RxDoctor Payments Data

Carla Hall, NP

Family · Kansas City, KSNPI 1750663803

Payments from drug & device makers

$1,359in general payments, 2019–2025

Across 68 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$195
  • Merck$166
  • Boston Scientific$146
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$135
  • Amgen$132
  • Novo Nordisk$131
  • plus $455 from 9 others

What the payments were for

  • Food & beverage$1,359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,359 in reported general payments places this provider in the 75th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$60,648
Medicare patients
253
Services billed
529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan113$115,412
JardianceEmpagliflozin95$76,754
FarxigaDapagliflozin Propanediol41$48,293
MounjaroTirzepatide23$23,019
EliquisApixaban17$18,254
OzempicSemaglutide20$17,940
Repatha SureclickEvolocumab17$9,290
Bumetanide73$4,009
Potassium Chloride74$2,065
Metoprolol Succinate111$1,590
Spironolactone117$1,314
Torsemide40$1,061
Furosemide103$536
Losartan Potassium60$496
Carvedilol47$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$42$115,412113 claims
Boehringer IngelheimJardiance$110$76,75495 claims
AstraZenecaFarxiga$195$48,29341 claims
PfizerEliquis$47$18,25417 claims
Novo NordiskOzempic$131$17,94020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,579 family providers in Kansas.

Other family in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →